Home › All Companies › AIM › Annual Report

AIM ImmunoTech Inc. (AIM) — Annual Report

AI-Powered SEC Filing Analysis

← All AIM filings
Latest Annual Report Filed: 2026-03-27

Key Insights

  • The company has experienced significant growth in its patent and trademark portfolio, indicating potential for future value creation.
  • The company has entered into several financing agreements with Streeterville Capital, LLC which provide additional capital to fund operations.
  • The company has implemented an employee stock purchase plan, which could help with talent retention and alignment with shareholder interests.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for AIM ImmunoTech Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.